Position of GWC lifted, all thanks to the Sivik Global healthcare LLC

The position of Sivik Global Healthcare LLC was increased in GW Pharmaceuticals PLC-(NASDAQ:GWPH) by an astounding 500% in the first quarter, in accordance with its most recent Form 13F filing with the SEC. The fund maintained possession of 30,000 shares of the stock of the biopharmaceutical company which is after the buying of 25,000 more shares in the period. GW Pharmaceuticals PLC- is accountable for 1.9% of Sivik Global Healthcare’s portfolio thus making its stock the 26th largest holding. Sivik Global Healthcare had ownership of 0.10% of GW Pharmaceuticals PLC- which amounts to $5,570,000 at the end of the recent quarter.

Several other big investors have also recently added to or backed away from their stakes in the company. Horan Capital Advisors LLC Purchased a new position in GW Pharmaceuticals PLC- within the first quarter which was worth $25,000. Exane Derivatives purchased a new position in GW Pharmaceuticals PLC- within the first quarter which was worth $28,000. Mckinley Capital Management LLC Delaware purchased a new position in GW Pharmaceuticals PLC- within the fourth quarter which was worth $30,000. Paragon Capital Management LLC purchased a new position in GW Pharmaceuticals PLC- within the first quarter which was worth $34,000 and finally Duncker Street & Co. Inc purchased a new position in GW Pharmaceuticals PLC-, also in the first quarter which was worth $34,000. Hedge funds and some other institutional investors own a large, 79.07% of the stock of the company.

Many other brokerages also recently commented on GWPH. BidaskClub cut down GW Pharmaceuticals PLC- from a ‘buy’ rating, down to a ‘hold’ rating in a research report that was on Thursday, the 21st of February. Meanwhile, Morgan Stanley restarted a ‘buy’ rating on shares of GW Pharmaceuticals PLC- in a report which was on the 9th of April, on Tuesday. Zacks Investment Research brought GW Pharmaceuticals up from a ‘hold’ to a ‘buy’ rating and then set a price objective of $193 for the company in a report on Thursday on the 11th of April. Oppenheimer also raised GW Pharmaceuticals PLC- from a rating of ‘market performs’ to ‘outperform’ and then lifted the price objective for the company to $234 (previously $162) in a report that was on the 7th of May on Tuesday.